NewLimit, co-founded by Brian Armstrong, has secured 130 million USD in Series B funding, boosting its total funding to over 170 million USD, including a previous 40 million USD from Series A.
The startup focuses on using AI for cell reprogramming to combat aging, part of a broader trend in Silicon Valley towards longevity ventures with substantial financial backing from renowned investors.
Leave a Reply